Switching from oral donepezil to rivastigmine transdermal patch in alzheimer's disease: 20-week extension phase results

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 12, Issue 5, 2010, Pages

  Sadowsky, Carl H ^a   Dengiz, Alan ^b   Meng, Xiangyi ^c   Olin, Jason T ^c  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Saint Joseph Mercy Health System   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; APPLICATION SITE REACTION; ARTICLE; BRADYCARDIA; CEREBELLUM INFARCTION; CLINICAL TRIAL; COMPULSIVE PERSONALITY DISORDER; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOTOR DYSFUNCTION; NAUSEA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SKIN IRRITATION; TABLET; TRANSDERMAL PATCH; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

EID: 78650626568     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.09m00852oli     Document Type: Article

References (23)

1. Doody RS, Stevens JC, Beck C, et al. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management of dementia (an evidence-based review). Neurology. 2001;56(9):1154-1166. PubMed
2. Forest Pharmaceuticals, Inc. Namenda. Prescribing Information. 2009. http://www.frx.com/pi/namenda_pi.pdf. Accessed May 6, 2009.
3. Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry. 2007;9(2):113-121. PubMed doi:10.4088/PCC.v09n0205
4. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23(11):2705-2713. PubMed doi:10.1185/030079907X233403
5. Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707-714. PubMed doi:10.1185/030079903125002450
6. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(3):129-138. PubMed doi:10.1185/030079902125000471
7. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl. 2002;(127):64-72. PubMed
8. Sadowsky CH, Farlow MR, Atkinson L, et al. Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry. 2005;7(2):43-48. PubMed doi:10.4088/PCC.v07n0201
9. Bartorelli L, Giraldi C, Saccardo M, et al. Upgrade Study Group. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin. 2005;21(11):1809-1818. PubMed doi:10.1185/030079905X65655
10. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
11. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318(7184):633-638. PubMed
12. Cummings J, Lefèvre G, Small G, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology. 2007;69(suppl 1):S10-S13. PubMed doi:10.1212/01.wnl.0000281846.40390.50
13. Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(suppl 1):S14-S22. PubMed doi:10.1212/01.wnl.0000281847.17519.e0
14. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22(5):485-491. PubMed doi:10.1002/gps.1806
15. Sadowsky CH, Dengiz A, Olin JT, et al. US38 Study Group. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2009;24(3):267-275. PubMed doi:10.1177/1533317509333037
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Arlington, VA: American Psychiatric Press, Inc; 2000.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. PubMed
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. PubMed doi:10.1016/0022-3956(75)90026-6
19. Ferris SH, Mackell JA, Mohs R, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S1-S12. PubMed doi:10.1097/00002093-199700112-00001
20. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39. PubMed doi:10.1097/00002093-199700112-00005
21. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314. PubMed
22. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46(2):210-215. PubMed
23. Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007;69(4 suppl 1):S23-S28. PubMed doi:10.1212/01.wnl.0000281848.25142.11